Article Information
History
- March 30, 2020.
Article Versions
- Version 1 (March 20, 2020 - 06:18).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Andrea Torneri1 (andrea.torneri{at}uantwerpen.be),
- Pieter Jules Karel Libin2 (pieter.libin{at}gmail.com),
- Joris Vanderlocht3 (jorisvanderlocht{at}bioqubeventures.com),
- Anne-Mieke Vandamme4 (annemie.vandamme{at}uzleuven.be),
- Johan Neyts4 (johan.neyts{at}kuleuven.be) and
- Niel Hens5,6 (niel.hens{at}uhasselt.be)
- 1 Centre for Health Economic Research and Modelling Infectious Diseases, University of Antwerp, Antwerp, Belgium;
- 2 Artificial intelligence lab, Department of computer science, Vrije Universiteit Brussel;
- 3 Interuniversity Institute of Biostatistics and statistical Bioinformatics, Data Science Institute,Hasselt University, Hasselt, Belgium;
- 4 KU Leuven - University of Leuven, Department of Microbiology and ImmunologyRega Institute for Medical Research, Clinical and epidemiological virology, Leuven, Belgium;
- 5 Hasselt University and University of Antwerp
- ↵* Corresponding author; email: niel.hens{at}uhasselt.be
Posted March 30, 2020.
A prospect on the use of antiviral drugs to control local outbreaks of COVID-19
